U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185269) titled 'The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE' on Sept. 09.
Brief Summary: This study will evaluate the effect and safety of 626 in patients with SLE
Study Start Date: Sept. 11
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SLE)
Intervention:
DRUG: 626
626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.
DRUG: 626
626 subcutaneous (SC) injection.
DRUG: Placebo
Placebo subcutaneous (SC) injection.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Published by HT Digital Content Serv...